Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Net Cash Flow: 2020-2024

Historic Net Cash Flow for Xeris Biopharma Holdings (XERS) over the last 5 years, with Dec 2024 value amounting to $4.1 million.

  • Xeris Biopharma Holdings' Net Cash Flow rose 2010.81% to $32.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $32.3 million, marking a year-over-year increase of 152.34%. This contributed to the annual value of $4.1 million for FY2024, which is 107.45% up from last year.
  • According to the latest figures from FY2024, Xeris Biopharma Holdings' Net Cash Flow is $4.1 million, which was up 107.45% from -$54.6 million recorded in FY2023.
  • Xeris Biopharma Holdings' 5-year Net Cash Flow high stood at $59.0 million for FY2022, and its period low was -$54.6 million during FY2023.
  • Over the past 3 years, Xeris Biopharma Holdings' median Net Cash Flow value was $4.1 million (recorded in 2024), while the average stood at $2.8 million.
  • As far as peak fluctuations go, Xeris Biopharma Holdings' Net Cash Flow crashed by 192.54% in 2023, and later soared by 107.45% in 2024.
  • Yearly analysis of 5 years shows Xeris Biopharma Holdings' Net Cash Flow stood at $18.1 million in 2020, then surged by 63.95% to $29.7 million in 2021, then soared by 98.96% to $59.0 million in 2022, then crashed by 192.54% to -$54.6 million in 2023, then soared by 107.45% to $4.1 million in 2024.